newsfilter
← Latest News
PR Newswire·

Keenova Announces New Presentations at the Sexual Medicine Society of North America Annual Meeting

MNK
  • Keenova Therapeutics will present data on men's health at the Sexual Medicine Society of North America annual meeting from October 8-11, 2026.
  • Two presentations will highlight clinical studies & real-world experience supporting XIAFLEX as a nonsurgical treatment for Peyronie's disease, including cases with ventral curvature.
  • A third presentation will feature Keenova's Men's Sexual Health Screener, a tool designed to facilitate clinician-patient discussions on sexual health concerns.
  • Peyronie's disease involves fibrous scar tissue causing penile curvature & affects an estimated 1 in 10 men in the U.S., though diagnosis rates remain low.
  • XIAFLEX is indicated for adult men with Peyronie's disease who have a palpable plaque & curvature deformity of at least 30 degrees.
  • A boxed warning highlights the risk of corporal rupture (penile fracture) or other serious penile injury, with 0.5% of patients in clinical studies reporting rupture.
  • XIAFLEX is available only through a restricted REMS program due to risks of serious penile injury.
  • The drug is contraindicated for plaques involving the penile urethra & in patients with a history of hypersensitivity to collagenase.
  • Adverse reactions in clinical trials included penile hematoma (65.5%), penile ecchymosis (14.5%), penile swelling, & penile pain.
  • Post-marketing reports include acute post-injection back pain, localized skin necrosis requiring surgery, & syncope leading to bodily injuries.
  • Keenova Therapeutics is a U.S.-focused branded therapeutics company headquartered in Dublin, Ireland, with manufacturing facilities in multiple U.S. states.